Alto Neuroscience is redefining psychiatry by developing personalized and highly effective medicines to help patients get better faster. Its artificial intelligence (AI)-enabled platform measures biomarkers like EEG and wearable data, behavioral patterns, genetics and other factors, to match patients with the treatment they are most likely to respond to.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 10/15/21 | $32,000,000 | Series A |
Able Partners Apeiron Investment Group  Risk and Return Tim Kendall What If Ventures Windham Venture Partners | undisclosed |
| 10/25/22 | $35,000,000 | Series B |
Alkeon Capital Apeiron Investment Group Gaingels Korify Capital Lightswitch Capital Novartis Pharma AG Sobrato Capital Valor Equity Partners Vine Ventures What If Ventures Windham Venture Partners | undisclosed |
| 01/30/23 | $25,000,000 | Series B |
Alpha Wave Ventures | undisclosed |
